Eisai has launched its insomnia drug Dayvigo in Japan, the second in a new class of medicines after Merck & Co’s Belsomra, which made its debut there in 2014.
Switzerland’s Idorsia says it is on course to file a potential next-generation insomnia drug around the end of this year after a second batch of supportive phase 3 trial results, although t
GSK looks like it is starting to show the benefit of a revamp of its business under chief executive Emma Walmsley, with recent product launches driving a 10% rise in sales
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.